17,261 trials
Colitis, Ulcerative
Primary: Percentage of Participants Who Achieved Clinical Remission in the Modified Mayo Score (MMS) at Week 8 — 17.1 percentage of participants
Traumatic Optic Neuropathy
Primary: Number of Participants With Change/Improvement Visual Acuity From the Beseline — 28; 3; 5 Participants
Escherichia Coli Diarrhea
Primary: Number and Percentage of Participants Experiencing Solicited Events by Symptom and Maximum Severity — 15; 14; 15; 15 Participants
Clear Cell Renal Cell Carcinoma · Stage I Renal Cell Cancer · Stage II Renal Cell Cancer
Primary: Number of Participants Who Could Undergo Partial Nephrectomy After Pazopanib Therapy — 6 Participants
Hereditary Sensory and Autonomic Neuropathy Type I
Primary: Charcot Marie Tooth Neuropathy Score — 25.67; 20.22 scores on a scale
Hormone-Resistant Prostate Cancer · Prostate Adenocarcinoma · Recurrent Prostate Carcinoma
Primary: Progression-free Survival (PFS) Based on the RECIST Criteria — 5.5; 3.7 months — p=0.02
Prostate Cancer
Primary: Treatment Tolerance (Genitourinary [GU] or Gastrointestinal [GI] Adverse Events) — 3 events
Epilepsy
Primary: Number Of Participants Who Experienced Severe OLE-Emergent AEs — 4 Participants
Endometriosis
Primary: Change From Baseline in the Monthly Mean Numerical Rating Score (NRS) for Endometriosis Pain — -0.35; -0.84; -1.00; -0.94 units on a scale — p=0.0464
Fabry Disease
Primary: Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs) — 1 Participants
Fabry Disease
Primary: Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs) — 0; 0; 0 Participants
Fabry Disease
Primary: Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs) — 2 Participants
Melanoma
Primary: One-year Overall Survival Rate (OSR) Estimated by Complete Case Method — 83.08; 83.33; 100 Percentage of Participants
End Stage Renal Disease
Primary: Number of Patients That Underwent Transplantation — 32 Participants
Endometriosis, Pain
Primary: Change From Baseline in the Monthly Mean Numerical Rating Score (NRS) for Endometriosis Pain at Week 12 — -0.88; -1.19; -1.25 units on a scale — p=0.2311